<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F34AC300-EA0B-49AC-9DE8-DF4287E54B4F"><gtr:id>F34AC300-EA0B-49AC-9DE8-DF4287E54B4F</gtr:id><gtr:name>The Garvan Institute for Medical Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F34AC300-EA0B-49AC-9DE8-DF4287E54B4F"><gtr:id>F34AC300-EA0B-49AC-9DE8-DF4287E54B4F</gtr:id><gtr:name>The Garvan Institute for Medical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B4D4F63-62DD-488C-AAA7-F3E1683C1D88"><gtr:id>7B4D4F63-62DD-488C-AAA7-F3E1683C1D88</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Rickinson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9935876F-FF1E-4555-A6DD-3818DEF017BC"><gtr:id>9935876F-FF1E-4555-A6DD-3818DEF017BC</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Moss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9901249"><gtr:id>AF12057F-8FCA-46F0-AD50-22629E4519CF</gtr:id><gtr:title>Cellular immunity to herpesvirus infection : studies with Epstein-Barr virus and human cytomegalovirus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9901249</gtr:grantReference><gtr:abstractText>Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) are common infections that most of us carry for life with no ill effect. But in people whose immune systems are suppressed, especially patients receiving bone marrow transplants after radiation treatment for leukaemia, these virus infections get out of control and become life-threatening. This reflects the important role that our immune system, especially that part of the immune system involving a type of white blood cell called a T cell, normally plays in controlling virus infections. We are studying the way human T cells normally control EBV and CMV infections, what parts of the virus are the main targets for T cell attack, and how the efficiency of T cell control and the choice of virus targets might change from the time immediately after infection, when the immune response first develops, to a point several years later when the virus is kept under control by long-lived ?memory? T cells. We are also developing new ways to isolate the important T cells from the blood of bone marrow donors, then to give them to the bone marrow recipients and in that way protect these patients from virus disease in the first few dangerous months after the transplant.</gtr:abstractText><gtr:technicalSummary>Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are common human herpesviruses, sometimes causing symptomatic primary infections but then persisting for life as apparently harmless passengers. Host T cell surveillance is critical for asymptomatic virus carriage, however, and T cell-immunocompromised patients reveal the full pathogenic effects of uncontrolled infection. These viruses therefore serve both as model agents to study the human T cell response to infection and as important pathogens in their own right. The Programme will focus on:
(i) Primary CD8+ T cell responses and the development of memory: we shall continue to follow primary EBV infections prospectively, studying the selection of particular epitope-specificities and T cell receptor (TCR) clonotypes from primary CD8+ T cell responses into memory, and initiate parallel studies on primary CMV infections in transplant recipients. We shall also explore the potential of two new model systems to examine epitope selection and TCR usage in primary responses to EBV.
(ii) CD8 immunodominance among viral antigens and immunoevasion : we shall extend work on the marked hierarchy of CD8 immunodominance among EBV lytic cycle antigens, and link this to mechanistic studies on a unique early lytic cycle protein which we find impairs antigen presentation to CD8+ T cells. We shall pursue our identification of new targets of the CMV-induced CD8 response by in vitro reactivation with a CMV strain deleted for the US2-11 immunoevasion genes and study how the presentation of these new targets by CMV-infected fibroblasts is affected by US2-11 action.
(iii) CD4+ T cell responses : we shall continue work characterizing the large CD4 memory response to CMV in terms of phenotype, function and antigenic specificity, and examine its age-dependent expansion against that seen for CMV-specific CD8 memory. We shall initiate parallel studies looking at hierarchies of CD4 immunodominance among EBV lytic cycle proteins, at the capacity of such responses to recognise lytically-infected cells and at the potential influence of viral evasion strategies on those parameters.
(iv) Immunological intervention against viral disease: we shall continue our contributions to translational work, extending the range of viral epitopes available for tetramer-based selection and adoptive CD8+ T cell therapy against CMV disease and developing protocols for the selection of CMV-specific CD4+ T cells. Looking further towards vaccine development, we shall extend our series of heterologous viral vectors carrying single or multiple CMV antigen inserts and examine their recognition by epitope-specific CD4+ and CD8+ T cells.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1608839</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Evasion of T cell recognition by EBV BNLF2a protein</gtr:description><gtr:id>94244DD1-1AF0-4F9A-8E78-A62B4CB68296</gtr:id><gtr:impact>Our research group has contibuted expertise in understanding the physiological relevance of the effects of the immune evasion protein in affecting the immune recognition of virally-infected cells.</gtr:impact><gtr:outcomeId>FR6xYLChs2v-1</gtr:outcomeId><gtr:partnerContribution>Collaborators have brought a greater understanding of the processes and effects of this immune evasion protein</gtr:partnerContribution><gtr:piContribution>Our research group has contibuted expertise in understanding the physiological relevance of the effects of the immune evasion protein in affecting the immune recognition of virally-infected cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Immune Regulation</gtr:department><gtr:description>MRC Centre for Immune Regulation</gtr:description><gtr:id>573CBCE4-1E3F-482F-B87B-8C0B5631C634</gtr:id><gtr:impact>Most of the outputs in this return</gtr:impact><gtr:outcomeId>jCCc2fSFAAU-1</gtr:outcomeId><gtr:partnerContribution>Core facilities and studentships</gtr:partnerContribution><gtr:piContribution>Theme Lead Cellular immunity to viral infections</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Garvan Institute for Medical Research</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Immunity to EBV in XLP patients and XLP carriers</gtr:description><gtr:id>4A90F483-D083-49D2-B7F2-AC0E556750D0</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>rCUVWHLjgRT-1</gtr:outcomeId><gtr:partnerContribution>Collaborators have brought access to patient samples, in particular analysis of lymphocyte sub-populations.</gtr:partnerContribution><gtr:piContribution>Our research group has contrubuted expertise in studying the EBV infection of lymphocyte subsets and immune assays of anti-viral T cell control.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Charity fund-raisers, Birmingham</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>86BF2212-1576-4225-ACEE-717CF6F186F3</gtr:id><gtr:impact>Hosting laboratory visits

Contuned support from community</gtr:impact><gtr:outcomeId>818FFF7F50D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media enquiries</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>944A571B-6195-47C3-BB09-D36ADFD2EDEE</gtr:id><gtr:impact>various articles in press

This activity increased public awareness of immune approaches to cancer therapy.</gtr:impact><gtr:outcomeId>cUQBFJrNa3c</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>439864</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Graham Taylor - Mechanisms of Endogenous Antigen Processing by the MHC Class II Pathway: Studies with Viral and Cellular Proteins</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>53F22E58-8B6B-4BFC-A5B7-8133F4E8E403</gtr:id><gtr:outcomeId>d1enSKYXNKV0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>173792</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heather Long - CD4+T Cells Recognising Human B Cell Lymphomas: Target Antigen Identification and Therapeutic Potential</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>295A8743-EA9A-473C-8CA6-4577513D16D2</gtr:id><gtr:outcomeId>BEV2dD29URP0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>281306</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Graham Taylor - Towards a Prophylactic Epstein-Barr Virus (EBV) Vaccine to Prevent EBV-Associated Malignancies</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>1FB2096C-B114-415D-AED3-3382CAA638CD</gtr:id><gtr:outcomeId>deQ1W2FcXzv0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participation in scientific advisory committees with concern for training strategy.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>683191F9-1237-4A4D-91CA-235F76D556A9</gtr:id><gtr:impact>This activity has informed the doctoral training guidelines of establishments with influence on the topics and contents of medical research projects.</gtr:impact><gtr:outcomeId>H8XVnzprquw</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participation in scientific advisory committees of research establishments.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4D49229C-50D9-4C3F-86F7-E42DC2A0D18E</gtr:id><gtr:impact>This activity has informed the strategic disciplinary themes of establishments with influence on the topics and contents of medical research projects.</gtr:impact><gtr:outcomeId>qxW9MToVPEL</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Prospective blood samples from infectious mononucleosis patients and large numbers of medical school entrants, for virologic/immunologic studies.</gtr:description><gtr:id>EE0E609B-A01A-4906-8F39-90CC9C19C6F1</gtr:id><gtr:impact>This data will be made freely available to other researchers within/beyond the University of Birmingham after journal publication.</gtr:impact><gtr:outcomeId>iAcrcnwughC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Prospective blood and serum samples</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FB4DF24B-8FC6-4584-AD23-E57D03731CAA</gtr:id><gtr:title>EBV meets its match.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83450e7665f631915c019eeb9d0218d3"><gtr:id>83450e7665f631915c019eeb9d0218d3</gtr:id><gtr:otherNames>Fox CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>aGE41XypKbR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F15AF885-C816-458C-8FA9-440172A877C3</gtr:id><gtr:title>Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45ee9f524afc1af2cb58609823aabd83"><gtr:id>45ee9f524afc1af2cb58609823aabd83</gtr:id><gtr:otherNames>Croft NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>664FF188EB4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC2032BE-5AD8-4F9C-B1CF-5F6989A804CD</gtr:id><gtr:title>Virus-specific cytotoxic T lymphocytes differentially express cell-surface leukocyte immunoglobulin-like receptor-1, an inhibitory receptor for class I major histocompatibility complex molecules.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6857253f8e4735ed33b2b3a51bf1e6f0"><gtr:id>6857253f8e4735ed33b2b3a51bf1e6f0</gtr:id><gtr:otherNames>Antrobus RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>BF51792820E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71EE97A3-F75E-48F0-8B74-506EF872B540</gtr:id><gtr:title>A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83450e7665f631915c019eeb9d0218d3"><gtr:id>83450e7665f631915c019eeb9d0218d3</gtr:id><gtr:otherNames>Fox CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>moECBX5gHsT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B0BA2D6-6A49-43FC-9577-C35F48AEA560</gtr:id><gtr:title>A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>28244CA5588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0418A7E9-FEE6-49FE-B3A5-DCA281A097A2</gtr:id><gtr:title>Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource?</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>G9ceuozecaw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C21FE05A-B364-4A55-9450-B32983303F1F</gtr:id><gtr:title>Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a0f4e705a3dff799b6610affff330a6"><gtr:id>6a0f4e705a3dff799b6610affff330a6</gtr:id><gtr:otherNames>Brooks JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>3A690A0B9AD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75C8597F-3F98-4FA3-9E6F-0249DA19B661</gtr:id><gtr:title>Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>0DF08B58CA8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA7D6B1A-2234-4169-A401-20382F11D794</gtr:id><gtr:title>Chronic graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptides.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ff92e47a69e6b02b6316c2d3dcc2d9f"><gtr:id>4ff92e47a69e6b02b6316c2d3dcc2d9f</gtr:id><gtr:otherNames>Smith HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>qm1c2c7fnkD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F83166C-16A5-462B-ADE5-EED8F8F32D97</gtr:id><gtr:title>Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d4d1fa9044196e26ca742b3bd347dd2"><gtr:id>2d4d1fa9044196e26ca742b3bd347dd2</gtr:id><gtr:otherNames>Goodyear O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>FN3W7kywyg6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58EC0F50-5068-47D6-A5E6-BBF78CAF208E</gtr:id><gtr:title>CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8b3c76e0897decbfdd4963d2da843bf"><gtr:id>e8b3c76e0897decbfdd4963d2da843bf</gtr:id><gtr:otherNames>McLarnon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>rrnnK2ccccp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D40BEA42-D2AC-4BDE-B7D3-D10A92ECBD54</gtr:id><gtr:title>T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>11656DA2428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AD3D292-FD94-4804-9B03-AD8590CB5CE9</gtr:id><gtr:title>Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fb8198871ffa3ada4c8c12e00fe628f"><gtr:id>4fb8198871ffa3ada4c8c12e00fe628f</gtr:id><gtr:otherNames>Horst D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>DE23BCCE972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E115E7CA-8346-4EB8-A12C-529C7150C18B</gtr:id><gtr:title>CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7226c39fef7a242bb5f9c59fec47be85"><gtr:id>7226c39fef7a242bb5f9c59fec47be85</gtr:id><gtr:otherNames>Pudney VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>9F35F1B97B9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29BC6FFB-A9D8-4CE4-B5CD-6A016294AB60</gtr:id><gtr:title>Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e09bcf346501396e9fdc1d487ed26a3"><gtr:id>4e09bcf346501396e9fdc1d487ed26a3</gtr:id><gtr:otherNames>Sauce D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>0908348E9A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F594151-59E7-4EB9-A9FC-B1E597138592</gtr:id><gtr:title>The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6c242a2c0170e908a3a3ef84075a453"><gtr:id>f6c242a2c0170e908a3a3ef84075a453</gtr:id><gtr:otherNames>Njie R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>4ABEFE87374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A26E72B-A70D-4FF8-A144-C03DF91E9D64</gtr:id><gtr:title>Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cbff024946625fe40da562d041f695e"><gtr:id>8cbff024946625fe40da562d041f695e</gtr:id><gtr:otherNames>Palendira U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>336752D8C83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A76813EF-BC6C-4D7B-B72D-A3D21CBCDF43</gtr:id><gtr:title>T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07b8d4142566ff4f71445dc7321a60f1"><gtr:id>07b8d4142566ff4f71445dc7321a60f1</gtr:id><gtr:otherNames>Mackay LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>1E3771B5CD4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FDD5266-D91B-4D7C-BB6A-0BD9BD1678BA</gtr:id><gtr:title>Latent cytomegalovirus infection amplifies CD8 T-lymphocyte mobilisation and egress in response to exercise.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58bbabb7721a17905c4bce710fcd6e05"><gtr:id>58bbabb7721a17905c4bce710fcd6e05</gtr:id><gtr:otherNames>Turner JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>jVSoN7DoGqz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3B662AB-1C17-4D68-B3FD-8D4694158D93</gtr:id><gtr:title>EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e09bcf346501396e9fdc1d487ed26a3"><gtr:id>4e09bcf346501396e9fdc1d487ed26a3</gtr:id><gtr:otherNames>Sauce D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>1712FD5AE72</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>345BF7BA-1617-4D9D-B455-5DDEA111F725</gtr:id><gtr:title>Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>k2qJyZMRWSx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5760560-476F-44B1-A20D-6F40C5053259</gtr:id><gtr:title>IL-7R alpha versus CCR7 and CD45 as markers of virus-specific CD8+ T cell differentiation: contrasting pictures in blood and tonsillar lymphoid tissue.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e09bcf346501396e9fdc1d487ed26a3"><gtr:id>4e09bcf346501396e9fdc1d487ed26a3</gtr:id><gtr:otherNames>Sauce D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>B66B6A9DBEA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CB90F13-AC88-4C6A-9DC1-DE62211EE8BE</gtr:id><gtr:title>Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>F9FEF02C1D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D877EF39-15F9-4C01-8589-FC0D2639B62F</gtr:id><gtr:title>The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ff25f40a28b2e1d339705fa678c5896"><gtr:id>0ff25f40a28b2e1d339705fa678c5896</gtr:id><gtr:otherNames>Weston VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>BZUc8fQBvfU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ECB0F9B-59EC-4A14-AFD6-D544E8811068</gtr:id><gtr:title>Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4298f1bc9f22f8a025503bb4fb95d22e"><gtr:id>4298f1bc9f22f8a025503bb4fb95d22e</gtr:id><gtr:otherNames>Leung CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>jhz6L44Q1Pg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>697ED241-CDFD-4456-B525-1DC908B7A1D9</gtr:id><gtr:title>The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6003a504a142016f62e8fe890b4b4e77"><gtr:id>6003a504a142016f62e8fe890b4b4e77</gtr:id><gtr:otherNames>Pourgheysari B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>UroNbxjitVs</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9901249</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>